正大天晴品牌怎么样申请店铺

我要投票

正大天晴在医疗用品行业中的票数：675 更新时间：2025-07-21

正大天晴是哪个国家的品牌？「正大天晴」是正大天晴药业集团股份有限公司旗下著名品牌。该品牌发源于江苏省连云港市，在1997年期间创立，经过多年的不懈努力和高速发展，现已成为行业的标杆品牌。

外推网助力正大天晴品牌出海！将品牌入驻外推网，定制正大天晴品牌推广信息，可以显著提高正大天晴产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

正大天晴药业集团股份有限公司，创建于1997年，高新技术企业，国内较大的肝健康药物研发和生产基地，集科研、生产和销售为一体的大型医药企业

正大天晴药业集团是集科研、生产和销售为一体的创新型医药集团企业，是国内肝健康药物研发和生产基地。

正大天晴始终将科技创新作为企业发展的重要战略，是国内创新药物研究投入较多的药企之一。随着企业的发展和研发能力的提升，正大天晴的研发费用投入已超过10亿元/年，并将逐步向跨国公司看齐。目前，研究院在研项目247个，其中一类新药31个，生物药32个。

正大天晴在连云港建有三个生产基地，总占地面积800余亩，包括占地160亩的孵化基地，占地200多亩的原料药基地，占地480亩的制剂基地。正大天晴制剂基地按照欧盟和美国FDA标准设计建设，小容量注射剂获得了全国首张GMP证书，口服固体制剂获得了江苏省首张GMP证书。2014年6月，制剂基地通过欧盟认证，获得了德国药品管理局颁发的欧盟认可的GMP认证证书。目前，正大天晴正在为四大拳头产品进军国际市场做准备，未来这些药物将成为正大天晴敲开国际市场的新利器。

正大天晴产品治疗领域涉及肝病、肿瘤、呼吸、感染、消化等多种疾病领域，14个年销售过亿元的产品形成了“亿元产品群”，其中年销售额过20亿元产品2个，分别为国家一类新药异甘草酸镁注射液（天晴甘美）和国内较早上市的恩替卡韦分散片（润众）。除强势肝病领域，抗肿瘤领域也形成了独特的产品线，血液肿瘤产品地西他滨、伊马替尼、达沙替尼为国内首仿；实体瘤产品卡培他滨获批上市。呼吸、抗生素、内分泌等领域，也将是企业未来发展的方向。

未来发展中，正大天晴药业将继续强化核心竞争力的打造，建立健全科学的研发体系，使公司的研发水平始终与国际前沿接轨。

Zhengda Tianqing Pharmaceutical Group Co., Ltd., founded in 1997, is a high-tech enterprise, a large domestic R & D and production base of liver health drugs, a large pharmaceutical enterprise integrating scientific research, production and sales. Zhengda Tianqing Pharmaceutical Group is an innovative pharmaceutical group enterprise integrating scientific research, production and sales, and a domestic R & D and production base of liver health drugs. Zhengda Tianqing has always regarded scientific and technological innovation as an important strategy for the development of enterprises, and is one of the pharmaceutical enterprises with more investment in innovative drug research in China. With the development of enterprises and the improvement of R & D capabilities, the R & D investment of Zhengda Tianqing has exceeded 1 billion yuan / year, and will gradually match with that of multinational companies. At present, there are 247 research projects in the Research Institute, including 31 first-class new drugs and 32 biological drugs. Zhengda Tianqing has three production bases in Lianyungang, covering an area of more than 800 mu, including 160 Mu incubation base, more than 200 mu API base and 480 Mu preparation base. Zhengda Tianqing preparation base is designed and constructed in accordance with EU and US FDA standards. Small volume injection has obtained the first GMP certificate in China, and oral solid preparation has obtained the first GMP certificate in Jiangsu Province. In June 2014, the preparation base passed the EU certification and obtained the EU recognized GMP certification issued by the German Drug Administration. At present, Zhengda Tianqing is preparing for the four major products to enter the international market. In the future, these drugs will become a new weapon for Zhengda Tianqing to open the international market. Zhengda Tianqing's product treatment field involves various disease fields such as liver disease, tumor, respiration, infection, digestion and so on. 14 products with annual sales of more than 100 million yuan have formed a "hundred million yuan product group", including 2 products with annual sales of more than 2 billion yuan, which are the national first-class new drug magnesium isoglycate injection solution (Tianqing Ganmei) and the earlier listed entecavir dispersible tablet (Runzhong). In addition to the strong liver disease field, the anti-tumor field has also formed a unique product line. The blood tumor products sitabin, imatinib and dasatinib are the first imitations in China; the solid tumor products capecitabine have been approved for listing. Respiratory, antibiotic, endocrine and other fields will also be the future development direction of the enterprise. In the future, Zhengda Tianqing Pharmaceutical Co., Ltd. will continue to strengthen the building of core competitiveness, establish a sound scientific research and development system, and keep the company's research and development level in line with the international forefront.

本文链接： https://brand.waitui.com/31672152f.html 联系电话：请联系客服添加联系邮箱：请联系客服添加